Literature DB >> 3925477

Effect of desipramine on control of ventilation and depression scores in patients with severe chronic obstructive pulmonary disease.

G H Gordon, T M Michiels, C K Mahutte, R W Light.   

Abstract

Decreased ventilatory responses to carbon dioxide (CO2) correlate with elevated scores on tests for depression in normal subjects and with episodes of endogenous depression in psychiatric patients. Patients with severe chronic obstructive pulmonary disease (COPD) frequently develop resting hypercapnia due to impaired ventilatory mechanics or drive, and may also have elevated scores on tests for depression. Tricyclic antidepressant drugs can improve ventilatory mechanics and possibly drive. We hypothesized that antidepressant drugs might enhance ventilatory drive and improve arterial blood gases in patients with severe COPD and that these improvements might correlate with improvement in depression scores. Therefore, we studied the effects of desipramine versus placebo on spirometry, resting arterial blood gases, hypercapnic ventilatory and mouth occlusion pressure responses, and scores on the Beck and Zung self-rated depression scales. In our patients the resting arterial CO2 (PaCO2) was found to depend almost equally on ventilatory mechanics and drive. In addition, patients with higher depression scores tended to have a lower PaCO2 when the severity of airways obstruction was taken into consideration. In a 16-week, double-blind, crossover comparison of desipramine with placebo, both treatments led to significant improvement in depression scores. Desipramine had no effects on resting PaCO2, spirometry, or ventilatory control.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925477     DOI: 10.1016/0165-1781(85)90036-8

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

1.  Models of care for late-life depression of the medically ill: examples from chronic obstructive pulmonary disease and stroke.

Authors:  Jimmy N Avari; George S Alexopoulos
Journal:  Am J Geriatr Psychiatry       Date:  2014-06-20       Impact factor: 4.105

Review 2.  Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes.

Authors:  A M Yohannes; G S Alexopoulos
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

Review 3.  Mood disorders and chronic obstructive pulmonary disease: current research and future needs.

Authors:  Greg L Clary; Scott M Palmer; P Murali Doraiswamy
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

Review 4.  Use of antidepressants in older patients with co-morbid medical conditions: guidance from studies of depression in somatic illness.

Authors:  Gary J Kennedy; Paula Marcus
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review.

Authors:  L van Ede; C J Yzermans; H J Brouwer
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

6.  Risk of depression in patients with chronic obstructive pulmonary disease and its determinants.

Authors:  J G van Manen; P J E Bindels; F W Dekker; C J IJzermans; J S van der Zee; E Schadé
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

Review 7.  Low dosage tricyclic antidepressants for depression.

Authors:  T Furukawa; H McGuire; C Barbui
Journal:  Cochrane Database Syst Rev       Date:  2003

8.  Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease.

Authors:  Justyna Pollok; Joep Em van Agteren; Kristin V Carson-Chahhoud
Journal:  Cochrane Database Syst Rev       Date:  2018-12-19

Review 9.  Strategies to improve anxiety and depression in patients with COPD: a mental health perspective.

Authors:  Athanasios Tselebis; Argyro Pachi; Ioannis Ilias; Epaminondas Kosmas; Dionisios Bratis; Georgios Moussas; Nikolaos Tzanakis
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-09       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.